Form 4: Spyre Therapeutics CMO Sells Shares Under 10b5-1 Plan

Chief Medical Officer Sheldon Sloan exercised options and sold 8,333 shares of Spyre Therapeutics at $75.00 per share under a pre-arranged trading plan.

Summary

• Sheldon Sloan, the Chief Medical Officer of Spyre Therapeutics, Inc., executed a transaction involving the exercise and sale of stock options on June 3, 2026.
• The executive exercised options to acquire 8,333 shares of common stock at an exercise price of $27.46 per share.
• All 8,333 shares were immediately sold at a price of $75.00 per share, resulting in total sale proceeds of $624,975.
• The transaction was conducted under a Rule 10b5-1 trading plan, which was previously adopted on June 20, 2025.
• Following these transactions, the reporting person holds 0 shares of common stock directly but retains 313,334 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it is an insider sale, it was pre-planned and represents only a small fraction of the executive's total option holdings.

Positives

• The sale was executed at $75.00, which is approximately 173% higher than the option exercise price of $27.46.
• The use of a Rule 10b5-1 trading plan provides a legal safe harbor and indicates the trade was planned well in advance (June 2025).
• The executive maintains a significant remaining interest in the company through 313,334 unexercised options.

Negatives

• The reporting person currently holds zero shares of common stock directly following the sale, having liquidated the entirety of the exercised position.

Risks

• Insider sales, even when planned, can sometimes be interpreted by the market as a lack of conviction in near-term price appreciation.
• The remaining options are subject to continued employment, creating a dependency on executive retention for future equity stability.

Future Outlook

The reporting person will continue to vest the remaining three-quarters of the original 400,000 share option grant in monthly installments over the next three years, provided they remain employed with the company.

Management Comments

• The transactions were executed pursuant to a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

StockSavvy.ai notes that in the biotechnology sector, executives frequently utilize 10b5-1 plans to diversify their portfolios and manage liquidity, especially after significant stock price appreciation following clinical or regulatory milestones.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard best practice for C-suite executives in publicly traded U.S. companies to avoid allegations of insider trading.
• A 'sell-to-cover' or 'exercise-and-sell' strategy is common among biotech executives whose compensation is heavily weighted toward options rather than cash.
• The 173% gain on the exercise price reflects performance that is currently outpacing many mid-cap biotech peers over the same vesting period.

Corporate Governance

Related Party Transactions

• The exercise of options and sale of stock by the Chief Medical Officer constitutes a related party transaction between the executive and the issuer.

Stakeholder Impact

• Shareholders may see a minor increase in the tradable float, though 8,333 shares is likely negligible relative to total volume.
• Investors often monitor these filings to gauge executive sentiment, though the 10b5-1 designation mitigates negative signaling.

Next Steps

• Continued monthly vesting of the remaining 313,334 stock options.
• Potential for future scheduled sales under the existing 10b5-1 plan.

Key Dates

Recommendation

The filing describes a routine, pre-planned insider transaction that does not change the fundamental outlook of the company. Investors should maintain their current positions while awaiting clinical data or broader financial reports.

Keywords

Spyre Therapeutics, SYRE, Insider Trading, Form 4, Sheldon Sloan, Stock Options, 10b5-1 Plan, Biotechnology, Executive Compensation